Patients with BRAF/+/melanomas had a higher probability of 2-year RFS compared to melanoma BRAF/−/patients at 62.9% (95% CI: 49.4–80%) vs. 57.7% (95% CI: 46.4–71.7%), respectively, p = 0.023. The gene discussed is BRAF; the disease is melanoma.